NAPROXEN tablet NAPROXEN SODIUM tablet

Χώρα: Ηνωμένες Πολιτείες

Γλώσσα: Αγγλικά

Πηγή: NLM (National Library of Medicine)

Αγόρασέ το τώρα

Δραστική ουσία:

NAPROXEN (UNII: 57Y76R9ATQ) (NAPROXEN - UNII:57Y76R9ATQ)

Διαθέσιμο από:

STAT Rx USA LLC

INN (Διεθνής Όνομα):

NAPROXEN

Σύνθεση:

NAPROXEN 500 mg

Οδός χορήγησης:

ORAL

Τρόπος διάθεσης:

PRESCRIPTION DRUG

Θεραπευτικές ενδείξεις:

Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: - For the relief of the signs and symptoms of rheumatoid arthritis - For the relief of the signs and symptoms of osteoarthritis - For the relief of the signs and symptoms of ankylosing spondylitis - For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: - For relief of the signs and symptoms of tendonitis - For relief of the signs and symptoms of bursitis - For relief of the signs and symptoms of acute gout - For the managem

Περίληψη προϊόντος:

500 mg: capsule shaped, light orange colored, uncoated tablets, having debossed with ‘G’ and ‘32’ on either side of break line on one side and ‘500’ on the other side. Packaged in light-resistant bottles of 30, 60 and 90. 30’s (bottle): NDC 42549-592-30 60’s (bottle): NDC 42549-592-60 90’s (bottle): NDC 42549-592-90

Καθεστώς αδειοδότησης:

Abbreviated New Drug Application

Φύλλο οδηγιών χρήσης

                                NAPROXEN SODIUM - NAPROXEN SODIUM TABLET
STAT Rx USA LLC
----------
MEDICATION GUIDE FOR NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDS)
(See the end of this Medication Guide for a list of prescription NSAID
medicines.)
What is the most important information I should know about medicines
called Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs)?
NSAID medicines may increase the chance of a heart attack or stroke
that
can lead to death. This chance increases:
•
with longer use of NSAID medicines
•
in people who have heart disease
NSAID medicines should never be used right before or after a heart
surgery
called a “coronary artery bypass graft (CABG).”
NSAID medicines can cause ulcers and bleeding in the stomach and
intestines at any time during treatment. Ulcers and bleeding:
•
can happen without warning symptoms
•
may cause death
The chance of a person getting an ulcer or bleeding increases with:
•
taking medicines called “corticosteroids” and “anticoagulants”
•
longer use
•
smoking
•
drinking alcohol
•
older age
•
having poor health
NSAID medicines should only be used:
•
exactly as prescribed
•
at the lowest dose possible for your treatment
•
for the shortest time needed
What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines are used to treat pain and redness, swelling, and heat
(inflammation) from medical
conditions such as:
•
different types of arthritis
•
menstrual cramps and other types of short-term pain
Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?
Do not take an NSAID medicine:
•
if you had an asthma attack, hives, or other allergic reaction with
aspirin or any other NSAID
medicine
•
for pain right before or after heart bypass surgery
Tell your healthcare provider:
•
about all your medical conditions.
•
about all of the medicines you take. NSAIDs and some other medicines
can interact with each
other and cause serious side effects. Keep a list of your medicines to
show to your healthcare
provider and pharmacist.
•
if you
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αρχείο Π.Χ.Π.

                                NAPROXEN - NAPROXEN TABLET
NAPROXEN SODIUM - NAPROXEN SODIUM TABLET
STAT RX USA LLC
----------
NAPROXEN TABLETS USP
NAPROXEN SODIUM TABLETS USP
RX ONLY
DESCRIPTION
Naproxen USP is a proprionic acid derivative related to the arylacetic
acid group of nonsteroidal anti-
inflammatory drugs.
The chemical names for naproxen USP and naproxen sodium USP are
(S)-6-methoxy-α-methyl-2-
naphthaleneacetic acid and (S)-6-methoxy-α-methyl-2-naphthaleneacetic
acid, sodium salt, respectively.
Naproxen USP and naproxen sodium USP have the following structures,
respectively:
Naproxen USP has a molecular weight of 230.26 and a molecular formula
of C
H O . Naproxen
sodium USP has a molecular weight of 252.23 and a molecular formula of
C
H NaO .
Naproxen USP is an odorless, white to off-white crystalline substance.
It is lipid-soluble, practically
insoluble in water at low pH and freely soluble in water at high pH.
The octanol/water partition
coefficient of naproxen USP at pH 7.4 is 1.6 to 1.8. Naproxen sodium
USP is a white to creamy white,
crystalline solid, freely soluble in water at neutral pH.
Naproxen tablets USP are available as light orange colored tablets
containing 250 mg of naproxen USP,
light orange colored tablets containing 375 mg of naproxen USP and
light orange colored tablets
containing 500 mg of naproxen USP for oral administration. The
inactive ingredients are
microcrystalline cellulose, croscarmellose sodium, iron oxides,
povidone and magnesium stearate.
Naproxen sodium tablets USP are available as blue tablets containing
275 mg of naproxen sodium USP
and as blue tablets containing 550 mg of naproxen sodium USP for oral
administration. The inactive
ingredients are croscarmellose sodium, colloidal silicon dioxide,
povidone, magnesium stearate,
microcrystalline cellulose and talc. The coating suspension for the
naproxen sodium 275 mg tablet may
contain Opadry blue 03F50544. The coating suspension for the naproxen
sodium 550 mg tablet may
contain Opadry blue 03F50544.
CLINICAL PHARMACOLOGY
PHARMACODYNAMICS
Naproxen 
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν

Προβολή ιστορικού εγγράφων